Venetoclax is a common treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). While it's effective, it needs close supervision to ensure safety. But how important is this constant monitoring, especially for patients at low or medium risk of tumor lysis syndrome (TLS)? Let's dive into some real-world experiences.

In a recent study, researchers looked at how crucial intensive lab checks are during Venetoclax treatment. They found that even patients with lower risk of TLS benefited from regular monitoring. It helped doctors spot potential issues early and make necessary adjustments.

One interesting point is that many doctors already follow these guidelines. They know that Venetoclax can cause TLS, which is when cancer cells break down too quickly, leading to kidney damage and other problems. So, they keep a close eye on patients' blood work.

But is this level of monitoring always necessary? Some experts suggest that it might be overkill for low-risk patients. They argue that resources could be better used elsewhere. On the other hand, others believe that even a small risk is worth careful watching.

In the end, it's about balancing risk and benefit. Intensive monitoring can catch problems early, but it also comes with costs and potential side effects. Patients and doctors need to work together to decide what's best.

Monitoring Venetoclax Treatment: Real-World Insights

Actions